Pamrevlumab Trials
Pamrevlumab Trials
Pamrevlumab, our proprietary fully human antibody, targets connective tissue growth factor (CTGF), the central mediator of tissue remodeling and fibrosis. Pamrevlumab represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body. Pamrevlumab is in Phase 3 clinical studies for the treatment of idiopathic pulmonary fibrosis, Duchenne muscular dystrophy, and locally advanced pancreatic cancer.
Pancreatic Cancer
LAPIS Study – FG-3019-087, Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination with Gemcitabine Plus Nab-paclitaxel (G/NP) as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer
For more information on the study, please contact
Precision PromiseSM Platform Study, Phase 2/3, Randomized, Open-label, A Multi-Center Trial Evaluating Multiple Regimens in Patients with Stage IV Metastatic Pancreatic Cancer
For more information on this study, please visit
Duchenne Muscular Dystrophy
LELANTOS Study – FG-3019-093 A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Learn more about pamrevlumab, DMD and the purpose of the LELANTOS study here, and download a printable version of this resource
LELANTOS TWO Study – FG-3019-094 A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Ambulatory Duchenne Muscular Dystrophy (DMD)
Learn more about pamrevlumab, DMD and the purpose of the LELANTOS TWO study here, and download a printable version of this resource
For more information on these studies, please contact
Idiopathic Pulmonary Fibrosis
ZEPHYRUS Study – FG-3019-091 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
ZEPHYRUS II Study – FG-3019-095 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
For more information on these studies, please contact
Pamrevlumab is an investigational drug and not approved for marketing by any regulatory authority.